Assessment Of Patient Interaction With A Dry Powder Inhaler Electronic Medication Monitor And Integrated System Within The Copd Foundation Patient Powered Research Network

SESSION TITLE: Obstructive Lung Disease Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: October 18-21, 2020 PURPOSE: Electronic medication monitors (EMM) and linked apps remotely monitor patient (pt) inhaler use, providing information on time of next dose, tracking inhaler use and symptom relevant factors (eg air quality). In asthma, EMMs have been associated with increased medication adherence, decreased rescue therapy use and symptom burden; however, few studies have included pts with chronic obstructive pulmonary disease (COPD) or using dry powder inhalers (DPI). METHODS: This open-label, single-arm, prospective observational cohort study recruited pts from the COPD Foundation’s Patient Powered Research Network (April–July 2019). Members were invited to participate if: aged ≥40 years, they used DPI maintenance therapy for COPD (self-reported) and had a compatible smartphone. Pts were excluded if enrolled in a COPD clinical study or reported off-label DPI use. After informed consent, pts received a controller inhaler EMM, rescue inhaler EMM (if requested), and downloaded the linked app. Pts completed a baseline questionnaire. Index date was at first connection of EMM to the app. Pts were followed for a minimum of 12 weeks up to 24 weeks to observe inhaler use and daily app interaction frequency. DPI maintenance treatment adherence was quantified as days therapy used as prescribed. Rescue medication use was quantified by puffs among pts with a rescue inhaler EMM. Pts completed questionnaires at 12 and 24 weeks (or study exit, if earlier). At baseline, pts completed the COPD Assessment Test and self-reported exacerbations in the prior year to determine Global initiative for Chronic Obstructive Lung Disease (GOLD) stage. RESULTS: Overall, 122 pts were enrolled. At baseline, most pts were ≥65 years (53.3%), female (63.9%), white non-Hispanic (95.1%), GOLD Stage B (51.6%) or D (43.4%). Overall, 9.0% of pts were current smokers, 5.7% had COPD for <1 year, 30.3% had concurrent asthma. The mean proportion of days (standard deviation [SD]) pts interacted with the app decreased over time from 59.5% (31.4) to 51.1% (33.5) and 41.3% (34.3) in days 1–30, 31–60 and 61–90, respectively. Mean DPI actuations (proportion of days [SD]) remained constant from days 1–30 (79.0% [23.7]) vs days 61–90 (79.5% [27.3]). In pts with a rescue EMM, mean rescue-free days (SD) increased from 18.5 (8.9 [days 1–30, n=51]) to 21.4 (9.6 [days 61–90, n=48]). Pts expressed (mean score out of 5, where the scale was 1 low–5 high, [SD]): confidence in EMM use (4.6 [1.1]), value from app reminders (4.3 [1.1]) and system satisfaction (4.1 [1.1]). CONCLUSIONS: Pts in a COPD cohort were satisfied using the EMM and associated app. Interaction with the app decreased over time. Pts also had high and consistent EMM adherence to DPI use and among pts with a rescue EMM, the number of rescue-free days increased. CLINICAL IMPLICATIONS: In this study, EMM use was associated with high pt satisfaction and frequent engagement with the app, which may aid COPD management. DISCLOSURES: No relevant relationships by Radmila Choate, source=Web Response Employee relationship with GlaxoSmithKline Please note: >$100000 Added 04/16/2020 by Kathryn Collison, source=Web Response, value=Salary Employee relationship with GlaxoSmithKline Please note: $20001 - $100000 Added 04/16/2020 by Kathryn Collison, source=Web Response, value=shares Employee relationship with ResMed (of which Propeller Health is an affiliate) Please note: >$100000 Added 04/16/2020 by Rahul Gondalia, source=Web Response, value=Salary No relevant relationships by Daniel Gratie, source=Web Response Employee relationship with ResMed Please note: >$100000 Added 04/16/2020 by Leanne Kaye, source=Web Response, value=Salary Patient Advisory Panel relationship with AstraZeneca Please note: $1-$1000 Added 04/16/2020 by John Linnell, source=Web Response, value=Consulting fee Advisory Committee Member relationship with GSK Please note: $1-$1000 Added 04/16/2020 by John Linnell, source=Web Response, value=Consulting fee No relevant relationships by Elisha Malanga, source=Web Response No relevant relationships by Gretchen McCreary, source=Web Response No relevant relationships by Cara Pasquale, source=Web Response Own stock relationship with GlaxoSmithKline Please note: $1-$1000 Added 04/16/2020 by Richard Stanford, source=Web Response, value=t Employee relationship with Propeller Health Please note: >$100000 Added 04/16/2020 by David Stempel, source=Web Response, value=Salary Former employee relationship with GlaxoSmithKline Please note: $5001 - $20000 Added 04/16/2020 by David Stempel, source=Web Response, value=Stockholder Employee relationship with GSK Please note: >$100000 Added 04/16/2020 by Ryan Tomlinson, source=Web Response, value=Salary No relevant relationships by Benjamin Wu, source=Web Response Consultant relationship with GSK Please note: $5001 - $20000 Added 03/02/2020 by Barbara Yawn, source=Web Response, value=Consulting fee Advisory Committee Member relationship with BI Please note: $1001 - $5000 Added 03/02/2020 by Barbara Yawn, source=Web Response, value=Honoraria Advisory Committee Member relationship with AZ Please note: $1001 - $5000 Added 03/02/2020 by Barbara Yawn, source=Web Response, value=Honoraria Advisory Committee Member relationship with Sunovian Please note: $1001 - $5000 Added 03/02/2020 by Barbara Yawn, source=Web Response, value=Honoraria